Evidence-based clinical trial design for chronic pain pharmacotherapy: A blueprint for ACTION

Pain

Volumn 152, Issue SUPPL.3, 2011, Pages

  Dworkin, Robert H ^a   Turk, Dennis C ^b   Katz, Nathaniel P ^c,d   Rowbotham, Michael C ^e   Peirce Sandner, Sarah ^a   Cerny, Igor ^f   Clingman, Chekesha S ^f   Eloff, Benjamin C ^f   Farrar, John T ^g   Kamp, Cornelia ^a   McDermott, Michael P ^a   Rappaport, Bob A ^f   Sanhai, Wendy R ^f  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Analgesic Solutions   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DULOXETINE; OPIATE; PLACEBO; PREGABALIN;

AGE DISTRIBUTION; CHRONIC PAIN; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DRUG DOSE REGIMEN; DRUG EFFICACY; EFFECT SIZE; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FIBROMYALGIA; HUMAN; LOW BACK PAIN; META ANALYSIS (TOPIC); NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ANALGESICS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 79951581600     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2010.11.008     Document Type: Review

References (94)

1. M. Backonja, A. Beydoun, K.R. Edwards, S.L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, and E. Garofalo Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial JAMA 280 1998 1831 1836 (Pubitemid 28544423)
2. R. Baron, R. Freynhagen, T.R. Tölle, C. Cloutier, T. Leon, T.K. Murphy, and K. Phillips The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy Pain 150 2010 420 427
3. A. Beydoun, A. Shaibani, M. Hopwood, and Y. Wan Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study Acta Neurol Scand 113 2006 395 404 (Pubitemid 44046325)
4. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
5. J.M. Bjordal, A. Klovning, A.E. Ljunggren, and L. Slordal Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials Eur J Pain 11 2007 125 138 (Pubitemid 44829965)
6. K. Bjune, A. Stubhaug, M.S. Dodgson, and H. Breivik Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section. Baseline pain-intensity is a determinant of assay-sensitivity in a postoperative analgesic trial Acta Anaesthesiol Scand 40 1996 399 407
7. D. Borsook, L. Becerra, and R. Hargreaves A role for fMRI in optimizing CNS drug development Nat Rev Drug Discov 5 2006 1 14
8. M.E. Cartwright, S. Cohen, J.C. Fleishaker, S. Madani, J.F. McLeod, B. Musser, and S.A. Williams Proof of concept: a PhRMA position paper with recommendations for best practice Clin Pharmacol Ther 87 2010 278 285
9. Center for Drug Evaluation and Research, United States Food and Drug Administration. Available from: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ DrugandBiologicApprovalReports/NMEDrugandNewBiologicApprovals/. [accessed 06.09.10].
10. A.S. Chappell, M.J. Ossanna, H. Liu-Seifert, S. Iyengar, V. Skljarevski, L.C. Li, R.M. Bennett, and H. Collins Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial Pain 146 2009 253 260
11. J. Cohen Statistical power analysis for the behavioral sciences 2nd ed. 1988 Lawrence Erlbaum Associates Hillsdale, NJ
12. G. Cruccu, C. Sommer, P. Anand, N. Attal, R. Baron, L. Garcia-Larrea, M. Haanpaa, T.S. Jensen, J. Serra, and R.D. Treede EFNS guidelines on neuropathic pain assessment: revised 2009 Eur J Neurol 17 2010 1010 1018
13. R.H. Dworkin, J. Katz, and M.J. Gitlin Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology 65 2005 S7 S19
14. R.H. Dworkin, D.C. Turk, M.P. McDermott, S. Peirce-Sandner, L.B. Burke, P. Cowan, J.T. Farrar, S. Hertz, S.N. Raja, B.A. Rappaport, C. Rauschkolb, and C. Sampaio Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations Pain 146 2009 238 244
15. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, R. Baron, N. Bellamy, L.B. Burke, A. Chappell, K. Chartier, C.S. Cleeland, A. Costello, P. Cowan, R. Dimitrova, S. Ellenberg, J.T. Farrar, J.A. French, I. Gilron, S. Hertz, A.R. Jadad, G.W. Jay, J. Kalliomaki, N.P. Katz, R.D. Kerns, D.C. Manning, M.P. McDermott, P.J. McGrath, A. Narayana, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, B.B. Reeve, T. Rhodes, C. Sampaio, D.M. Simpson, J.W. Stauffer, G. Stucki, J. Tobias, R.E. White, and J. Witter Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations Pain 149 2010 177 193
16. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, M.P. McDermott, J.T. Farrar, S. Hertz, N.P. Katz, S.N. Raja, and B.A. Rappaport Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database Pain 150 2010 12 16
17. R.H. Dworkin, D.C. Turk, K.W. Wyrwich, D. Beaton, C.S. Cleeland, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, R.D. Kerns, D.N. Ader, N. Brandenburg, L.B. Burke, D. Cella, J. Chandler, P. Cowan, R. Dimitrova, R. Dionne, S. Hertz, A.R. Jadad, N.P. Katz, H. Kehlet, L.D. Kramer, D.C. Manning, C. McCormick, M.P. McDermott, H.J. McQuay, S. Patel, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, D.A. Revicki, M. Rothman, K.E. Schmader, B.R. Stacey Stauffer, J.W. Stauffer, T. von Stein, R.E. White, J. Witter, and S. Zavisic Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121 (Pubitemid 351147828)
18. J.T. Farrar, R.H. Dworkin, and M.B. Max Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable J Pain Symptom Manage 31 2006 369 377
19. N.B. Finnerup, S.H. Sindrup, and T.S. Jensen The evidence for pharmacological treatment of neuropathic pain Pain 150 2010 573 581
20. T.R. Fleming Clinical trials: discerning hype from substance Ann Intern Med 153 2010 400 406
21. N. Freemantle, M. Calvert, J. Wood, J. Eastaugh, and C. Griffin Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289 2003 2554 2559 (Pubitemid 37430157)
22. R. Freynhagen, K. Strojek, T. Griesing, E. Whalen, and M. Balkenohl Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens Pain 115 2005 254 263 (Pubitemid 40725282)
23. B.S. Galer, D. Lee, T. Ma, B. Nagle, and T.G. Schlagheck MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or recution in tolerance Pain 115 2005 284 295 (Pubitemid 40725285)
24. K. Hamunen, and E. Kalso A systematic review of trial methodology, using the placebo groups of randomized controlled trials in paediatric postoperative pain Pain 116 2005 146 158 (Pubitemid 40834322)
25. R.E. Harris, D.A. Williams, S.A. McLean, A. Sen, M. Hufford, R.M. Gendreau, R.H. Gracely, and D.J. Clauw Characterization and consequences of pain variability in individuals with fibromyalgia Arthritis Rheum 52 2005 3670 3674 (Pubitemid 41612240)
26. M.T. Harting, F. Jimenez, and C.S. Cox Jr The pulmonary first-pass effect, xenotransplantation and translation to clinical trials: a commentary Brain 131 2008 1 2
27. W. Hauser, K. Bernardy, N. Uceyler, and C. Sommer Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Pain 145 2009 69 81
28. J. Hippisley-Cox, and C. Coupland Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis BMJ 330 2005 1366 1369 (Pubitemid 40839565)
29. Institute of Medicine. Transforming clinical research in the United States: challenges and opportunities. Washington, DC: The National Academies Press, 2010.
30. International Conference on Harmonization. E10: Choice of control groups and related issues in clinical trials. Available from: www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm125912.pdf. [accessed 24.11.10].
31. J.P.A. Ioannidis Why most published research findings are false PLoS Med 2 2005 e124
32. M.C. Irizarry, D.J. Webb, Z. Ali, B.A. Chizh, M. Gold, F.J. Kinrade, P.D. Meisner, D. Blum, M.T. Silver, and J.G. Weil Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials Clin J Pain 25 2009 469 476
33. J. Katz, N.B. Finnerup, and R.H. Dworkin Clinical trial outcome in neuropathic pain: relationship to study characteristics Neurology 70 2008 263 272 (Pubitemid 351156805)
34. N. Katz Methodological issues in clinical trials of opioids for chronic pain Neurology 65 2005 S32 S49
35. A. Khan, S. Khan, and W.A. Brown Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 5 2002 193 197
36. P. Knipschild The false positive therapeutic trial J Clin Epidemiol 55 2002 1191 1195 (Pubitemid 36110616)
37. P. Knipschild, P. Leffers, and A.R. Feinstein The qualification period J Clin Epidemiol 44 1991 461 464
38. K.A. Kobak, J.M. Kane, M.E. Thase, and A.A. Nierenberg Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 27 2007 1 5 (Pubitemid 46105756)
39. S.A. Kvaal, K.R. Lofland, and C. Nigro Clinical correlates of pain variability in chronic pain J Back Musculoskelet Rehabil 13 1999 87 92
40. E.M. Laska, A. Sunshine, J.A. Wanderling, and M.J. Meisner Quantitative differences in aspirin analgesia in three models of clinical pain J Clin Pharmacol 22 1982 531 542 (Pubitemid 13170116)
41. K. Lee, P. Bacchetti, and I. Sim Publication of clinical trials supporting successful new drug applications: a literature analysis PLoS Med 5 2008 1348 1356
42. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 2nd ed. 2002 Wiley Interscience Hoboken, NJ
43. K.S. Liu, D.B. Snavely, W.A. Ball, C.R. Lines, S.A. Reines, and W.Z. Potter Is bigger better for depression trials? J Psychiatr Res 42 2008 622 630 (Pubitemid 351626061)
44. L.A. Machado, S.J. Kamper, R.D. Herbert, C.G. Maher, and J.H. McAuley Analgesic effects of treatments for non-specific low back pain: a meta-analysis of placebo-controlled randomized trials Rheumatology 48 2009 520 527
45. C. Maier, R. Baron, T.R. Tolle, A. Binder, N. Birbaumer, F. Birklein, J. Gierthmuhlen, H. Flor, C. Geber, V. Huge, E.K. Krumova, G.B. Landwehrmeyer, W. Magerl, C. Maihofner, H. Richter, R. Rolke, A. Scherens, A. Schwarz, C. Sommer, V. Tronnier, N. Uceyler, M. Valet, G. Wasner, and R.D. Treede Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes Pain 150 2010 439 450
46. J. Mao Translational pain research: achievements and challenges J Pain 10 2009 1001 1011
47. H. McQuay, D. Carrol, and A. Moore Variation in the placebo effect in randomized controlled trials of analgesics: all is as blind as it seems Pain 64 1995 331 335 (Pubitemid 26132445)
48. I. Melnikova Pain market Nat Rev Drug Discov 9 2010 589 590
49. J.S. Mogil Animal models of pain: progress and challenges Nat Rev Neurosci 10 2009 283 294
50. J.S. Mogil, K.D. Davis, and S.W. Derbyshire The necessity of animal models in pain research Pain 151 2010 12 17
51. G. Molenberghs, and M.G. Kenward Missing data in clinical studies 2007 Wiley Chichester, UK
52. R.A. Moore, S.S. Smugar, H. Wang, P.M. Peloso, and A. Gammaitoni Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials Pain 151 2010 592 597
53. National Research Council. The prevention and treatment of missing data in clinical trials. Washington, DC: The National Academies Press, 2010.
54. E. Nüesch, S. Reichenbach, S. Trelle, A.W.S. Rutjes, K. Liewald, R. Sterchi, D.G. Altmann, and P. Jüni The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study Arthritis Rheum 61 2009 1633 1641
55. A.B. O'Connor The need for improved access to FDA reviews JAMA 302 2009 191 193
56. M.W. Otto, and A.A. Nierenberg Assay sensitivity, failed clinical trials, and the conduct of science Psychother Psychosom 71 2002 241 243
57. P. Petrovic, E. Kalso, K.M. Petersson, J. Andersson, P. Fransson, and M. Ingvar A prefrontal non-opioid mechanism in placebo analgesia Pain 150 2010 59 65
58. Pfizer protocol A0081071. A randomized double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Available from: www.clinicalstudyresults.org/drugdetails/?drug-name-id=203&indication- keyword=neuropathy&sort=c.company-name&page=2&drug-id=3972. [accessed 23.11.10].
59. S.N. Quessy The challenges of translational research for analgesics: the state of knowledge needs upgrading and some uncomfortable deficiencies remain to be urgently addressed J Pain 11 2010 698 700
60. S.N. Quessy Where are the new analgesics? An alternative approach to early phase analgesic trials using a multivariable input model with adaptively allocated enrichment Pain 151 2010 247 250
61. S.N. Quessy, and M.C. Rowbotham Placebo response in neuropathic pain trials Pain 138 2008 479 483
62. B.A. Rappaport, I. Cerny, and W.R. Sanhai ACTION on the prevention of chronic pain after surgery Anesthesiology 112 2010 509 510
63. A.S. Rice, D. Cimino-Brown, J.C. Eisenach, V.K. Kontinen, M.L. Lacroix-Fralish, I. Machin, Preclinical Pain Consortium, J.S. Mogil, and T. Stohr Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards Pain 139 2008 243 247
64. R. Rolke, R. Baron, C. Maier, T.R. Tolle, R.D. Treede, A. Beyer, A. Binder, N. Birbaumer, F. Birklein, I.C. Botefur, S. Braune, H. Flor, V. Huge, R. Klug, G.B. Landwehrmeyer, W. Magerl, C. Maihofner, C. Rolko, C. Schaub, A. Scherens, T. Sprenger, M. Valet, and B. Wasserka Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values Pain 123 2006 231 243
65. P.M. Rothwell External validity of randomized controlled trials: "to whom do the results of this trial apply?" Lancet 365 2005 82 93 (Pubitemid 40082150)
66. M.C. Rowbotham The impact of selective publication on clinical research in pain Pain 140 2008 401 404
67. M.C. Rowbotham The case for publishing 'negative' trials Pain 146 2009 225 226
68. M.C. Rowbotham, N. Harden, B. Stacey, P. Bernstein, and L. Magnus-Miller Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial JAMA 280 1998 1837 1842 (Pubitemid 28544424)
69. B.R. Rutherford, J.R. Sneed, and S.P. Roose Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials Psychother Psychosom 78 2009 172 181
70. J. Scholz, R.J. Mannion, D.E. Hord, R.S. Griffin, B. Rawal, H. Zheng, D. Scoffings, A. Phillips, J. Guo, R.J. Laing, S. Abdi, I. Decosterd, and C.J. Woolf A novel tool for the assessment of pain: validation in low back pain PLoS Med 6 2009 e1000047
71. D.M. Simpson, G. Schifitto, D.B. Clifford, T.K. Murphy, E. Durso-De Cruz, P. Glue, E. Whalen, B. Emir, G.N. Scott, and R. Freeman Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial Neurology 74 2010 413 420
72. V. Skljarevski, D. Desaiah, H. Liu-Seifert, Q. Zhang, A.S. Chappell, M.J. Detke, S. Iyengar, J.H. Atkinson, and M. Backonja Efficacy and safety of duloxetine in patients with chronic low back pain Spine (Phila Pa 1976) 35 2010 E578 E585
73. V. Skljarevski, M. Ossanna, H. Liu-Seifert, A. Chappell, S. Iyengar, M. Detke, and M. Backonja A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain Eur J Neurol 16 2009 1041 1048
74. B.R. Stacey, J.A. Barrett, E. Whalen, K.F. Phillips, and M.C. Rowbotham Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief J Pain 9 2008 1006 1017
75. J.A.C. Sterne, P. Jüni, K.F. Schulz, D.G. Altman, C. Bartlett, and M. Egger Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research Stat Med 21 2002 1513 1524 (Pubitemid 34746060)
76. D.C. Turk, R.H. Dworkin, L.B. Burke, R. Gershon, M. Rothman, J. Scott, R.R. Allen, J.H. Atkinson, J. Chandler, C. Cleeland, P. Cowan, R. Dimitrova, R. Dionne, J.T. Farrar, J.A. Haythornthwaite, S. Hertz, A.R. Jadad, M.P. Jensen, D. Kellstein, R.D. Kerns, D.C. Manning, S. Martin, M.B. Max, M.P. McDermott, P. McGrath, D.E. Moulin, T. Nurmikko, S. Quessy, S. Raja, B.A. Rappaport, C. Rauschkolb, J.P. Robinson, M.A. Royal, L. Simon, J.W. Stauffer, G. Stucki, J. Tollett, T. von Stein, M.S. Wallace, J. Wernicke, R.E. White, A.C. Williams, J. Witter, and K.W. Wyrwich Initiative on methods, measurement and pain assessment in clinical trials. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations Pain 125 2006 208 215 (Pubitemid 44711972)
77. D.C. Turk, R.H. Dworkin, M.P. McDermott, N. Bellamy, L.B. Burke, J.M. Chandler, C.S. Cleeland, P. Cowan, R. Dimitrova, J.T. Farrar, S. Hertz, J.F. Heyse, S. Iyengar, J.R. Jadad, G.W. Jay, J.A. Jermano, N.P. Katz, D.C. Manning, S. Martin, M.B. Max, P. McGrath, H.J. McQuay, S. Quessy, B.A. Rappaport, D.A. Revicki, M. Rothman, J.W. Stauffer, O. Svensson, R.E. White, and J. Witter Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations Pain 139 2008 485 493
78. E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell, and R. Rosenthal Selective publication of antidepressant trials and its influence on apparent efficacy N Engl J Med 358 2008 252 260
79. United States Food and Drug Administration. Solicitation, offer and award, 2010. Available from: https://www.fbo.gov/download/46c/ 46c30ab3d6d5b848a8f853dea6701e86/ACTION-SOL,-FDA-223-SOL-00263,-Posted-07.21. 2010.pdf. [accessed 26.11.10].
80. M.W. van Tulder, M. Suttorp, S. Morton, L.M. Bouter, and P. Shekelle Empirical evidence of an association between internal validity and effect size in randomized controlled trials of low-back pain Spine (Phila Pa 1976) 34 2009 1685 1692
81. S.S. Vedula, L. Bero, R.W. Scherer, and K. Dickersin Outcome reporting in industry-sponsored trials of gabapentin for off-label use N Engl J Med 361 2009 1963 1971
82. A.I. Vinik, M. Tuchman, B. Safirstein, C. Corder, L. Kirby, K. Wilks, S. Quessy, D. Blum, J. Grainger, J. White, and M. Silver Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies Pain 128 2007 169 179 (Pubitemid 46216610)
83. T.D. Wager, and M. Roy Separate mechanisms for placebo and opiate analgesia? Pain 150 2010 8 9
84. A. Whitehead Meta-analysis of controlled clinical trials 2002 John Wiley and Sons Chichester, UK
85. A.C. de C Williams, H.T.O. Davies, and Y. Chadury Simple pain rating scales hide complex idiosyncratic meanings Pain 85 2000 457 463 (Pubitemid 30214173)
86. L. Wood, M. Egger, L.L. Gluud, K.F. Schulz, P. Jüni, D.G. Altman, C. Gluud, R.M. Martin, A.J.G. Wood, and J.A.C. Sterne Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study BMJ 336 2008 601 605 (Pubitemid 351439518)
87. J. Woodcock A difficult balance: pain management, drug safety, and the FDA N Engl J Med 361 2009 2105 2107
88. J. Woodcock, J. Witter, and R.A. Dionne Stimulating the development of mechanism-based individualized pain therapies Nat Rev Drug Discov 6 2007 703 710 (Pubitemid 47338179)
89. C.J. Woolf Pain: moving from symptom control toward mechanism-specific pharmacologic management Ann Intern Med 140 2004 441 451 (Pubitemid 38327332)
90. C.J. Woolf, G.J. Bennett, M. Doherty, R. Dubner, B. Kidd, M. Koltzenburg, R. Lipton, J.D. Loeser, R. Payne, and E. Torebjork Towards a mechanism-based classification of pain? Pain 77 1998 227 229 (Pubitemid 28451510)
91. XenoPort, Inc. Phase II results for GSK1838262 (XP13512) reported for neuropathic pain associated with diabetic peripheral neuropathy; 2009. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=187883&p=irol- newsArticle&ID=1280577&highlight=. [accessed 23.11.10].
92. W. Zhang, J. Robertson, A.C. Jones, P.A. Dieppe, and M. Doherty The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials Ann Rheum Dis 67 2008 1716 1723
93. D. Ziegler, Y.L. Pritchett, F. Wang, D. Desaiah, M.J. Robinson, J.A. Hall, and A.S. Chappell Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain Diabetes Care 30 2007 664 669 (Pubitemid 46354350)
94. D.L. Zimbroff Patient and rater education of expectations in clinical trials (PREECT) J Clin Psychopharmacol 21 2001 251 252 (Pubitemid 32221074)